Directors' Profiles

Professor John Shine
Professor John Shine
Chairman
Paul Perreault
Paul Perreault
Chief Executive Officer and Managing Director
David Anstice
David Anstice
Bruce Brook
Bruce Brook
Megan Clark
Megan Clark AC
Marie McDonald
Marie McDonald
Christine O
Christine O'Reilly
Maurice Renshaw
Maurice Renshaw
Tadataka Tachi Yamada
Tadataka 'Tachi' Yamada KBE
Ed Bailey
Edward Bailey
Company Secretary

John Shine, AC

BSc (Hon), PhD, DSc, FAA - (Age 71)

Pharmaceutical Industry and Medicine (resident in New South Wales)
Independent: Yes

Chairman

Professor John Shine AC was appointed to the CSL Board in June 2006 and became Chairman in October 2011. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine was Executive Director of the Garvan Institute of Medical Research from 1990 - 2012. He was also formerly President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory) and Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science, Engineering and Innovation Council. Professor Shine was awarded the 2010 Prime Minister’s Prize for Science and, in 2017, a Companion of the Order of Australia (AC).

Professor Shine is Chairman of the Nomination Committee and a member of the Innovation and Development Committee.

Paul Perreault

BA Psychology – (Age 60)

Independent: No

 

Chief Executive Officer and Managing Director

Paul was appointed to the CSL Board in February 2013 and was appointed as the Chief Executive Officer and Managing Director in July 2013. He joined a CSL predecessor company in 1997 and has held senior roles in sales, marketing and operations with his most recent prior position being President, CSL Behring. Paul has also worked in senior leadership roles with Wyeth, Centeon, Aventis Bioservices and Aventis Behring. He was previously Chairman of the Global Board for the Plasma Protein Therapeutics Association. Paul has had more than 30 years’ experience in the global healthcare industry.

David Anstice

BEc – (Age 69)

International Pharmaceutical Industry (resident in Pennsylvania, US) 
Independent: Yes

Mr David Anstice was appointed to the CSL Board in September 2008. He was a long-time Member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 45 years’ experience in the global pharmaceutical industry. Until his retirement in August 2008, Mr Anstice was for many years a senior executive of Merck & Co., Inc., serving at various times as President of Human Health for US/Canada/ Latin America, Europe and Asia, and at retirement was an Executive Vice President. He is a Director of Alkermes Plc, Dublin, Ireland, and a Director of the United States Studies Centre at the University of Sydney.

Mr Anstice is Chairman of the Human Resources and Remuneration Committee, and a member of the Innovation and Development Committee and the Nomination Committee.

Bruce Book

BCom, BAcc, FCA, MAICD – (Age 62)

Finance and Management (resident in Victoria) 
Independent: Yes

Mr Bruce Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Boart Longyear Limited, Lihir Gold Limited and Consolidated Minerals Limited. During his executive career, he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.

Mr Brook is Chairman of the Audit and Risk Management Committee and a member of the Nomination Committee.

Megan Clark AC

BSc (Hons), PhD – (Age 59)

Science, Engineering and Management
Independent: Yes

Dr Megan Clark AC was appointed to the CSL Board in February 2016. She is currently a Director of Rio Tinto and Care Australia and a Member of the Australian advisory board of the Bank of America Merrill Lynch. Dr Clark was Chief Executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 to 2014. Prior to CSIRO, she was a Director at NM Rothschild and Sons (Australia) and was Vice President Technology and subsequently Vice President Health, Safety and Environment at BHP Billiton from 2003 to 2008.

Ms Clark is a member of the Human Resources Committee, the Innovation and Development Committee and the Nomination Committee.

Marie McDonald

BSc (Hon), LLB (Hon) – (Age 61)

Law (resident in Victoria) 
Independent: Yes

Ms Marie McDonald was appointed to the CSL Board in August 2013. For many years she has practised in company and commercial law and she was a partner of Ashurst (formerly Blake Dawson) until July 2014. Ms McDonald is currently a Director of Nanosonics Limited, The Walter and Eliza Hall Institute of Medical Research and Nufarm Limited. She was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia from 2012 to 2013, having previously been the Deputy Chair, and was also a Member of the Australian Takeovers Panel from 2001 to 2010.

Ms McDonald is a member of the Audit and Risk Management Committee and the Nomination Committee.

Christine O'Reilly

BBus – (Age 56)

Finance and Infrastructure (resident in Victoria) 
Independent: Yes

Ms Christine O’Reilly was appointed to the CSL Board in February 2011. She is a Director of Transurban, Energy Australia, Medibank Private Limited and Baker Heart & Diabetes Institute. Ms O’Reilly has in excess of 30 years financial and operational business experience in domestic and off-shore organisations. During her executive career, she was Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management and prior to that was the Chief Executive Officer of the GasNet Australia Group.

Ms O’Reilly is a member of the Audit and Risk Management Committee, the Human Resources and Remuneration Committee, and the Nomination Committee.

Maurice Renshaw

BPharm – (Age 70)

International Pharmaceutical Industry (resident in New South Wales) 
Independent: Yes

the CSL Board in July 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 35 years’ experience in the global pharmaceutical industry with responsibility for R&D, Regulatory, Manufacturing, Finance, Marketing and General Management across Europe, the US and Asia including Japan and China.

Mr Renshaw is Chairman of the Innovation and Development Committee and a member of the Nomination Committee.

Tadataka 'Tachi' Yamada KBE

BPharm – (Age 72)

International Pharmaceutical Industry and Medicine (resident in Washington, US) 
Independent: Yes

Dr Tadataka Yamada was appointed to the CSL Board in September 2016. He is presently a Venture Partner at Frazier Healthcare Partners, a leading provider of growth capital to healthcare companies, a position that he has held since 2015. Prior to this, he was the Chief Medical and Scientific Officer at Takeda Pharmaceuticals, as well as a Member of the Board. Prior to Takeda, Dr Yamada was President of the Bill & Melinda Gates Foundation Global Health Program and prior to that was Chairman of Research and Development at GlaxoSmithKline. He currently serves as a Director of Agilent Technologies, Inc. and the Clinton Health Access Initiative and a Member of the Council of the National Academy of Medicine. Dr Yamada is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of Physicians.

Dr Yamada is a Member of the Innovation and Development Committee and the Nomination Committee.

Ed Bailey

LLB, BCom, FGIA – (Age 51)

Company Secretary